Daratumumab for autoimmune diseases: a systematic review
Objective Refractory autoimmune diseases remain a significant challenge in clinical practice and new therapeutic options are needed. This systematic review evaluates the existing reported data on the CD38-targeting antibody daratumumab as a new therapeutic approach in autoantibody-mediated autoimmun...
Saved in:
Main Authors: | Martin Krusche, Ina Kötter, Lennard Ostendorf, Nikolas Ruffer, Marie-Therese Holzer, Tobias B. Huber |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-12-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/9/4/e003604.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01) -
The effects of magnesium supplementation in autoimmune rheumatic diseases
by: Aaron Lerner, et al.
Published: (2024-11-01) -
Deep learning-based prediction of autoimmune diseases
by: Donghong Yang, et al.
Published: (2025-02-01) -
The impact of gut microbiome on neuro-autoimmune demyelinating diseases
by: Pouria Abolfazli, et al.
Published: (2024-10-01) -
Effect of COVID-19 on Severity of Signs and Symptoms of Autoimmune Diseases
by: Ramand Mohammed Haji, et al.
Published: (2022-04-01)